Shares in RTW Biotech Opportunities (LON:RTW) firmed after the healthcare trust flagged private portfolio company Windward’s (NASDAQ:WWB) strong NASDAQ IPO (initial public offering) to investors.
Windward’s shares soared 68% to close at $28.50 in debut dealings on 13 November. This first day closing valuation represented a 180% step-up from RTW Bio’s prior holding value at 31 October 2026 and a 196% step-up from cost.
Admittedly, Windward is a small holding for RTW Bio. As at 31 October 2026, Windward spoke for just 0.8% of NAV (net asset value). Nevertheless, the successful flotation showcases RTW Bio’s ability to spot and back promising biotech companies at an early stage.
What does Windward do?
For the uninitiated, Windward is a clinical-stage biotech. It is developing antibody medicines engineered to be long acting and offer a more convenient product presentation for patients with serious respiratory and dermatologic diseases.
RTW Bio has invested a total of $7 million in Windward. At the IPO, it sold 10 million shares at $17 for gross proceeds of $175 million.
Concurrently, French pharma titan Sanofi (EPA:SAN) is investing $50 million in a private placement at the IPO price, bringing total gross proceeds to $225 million.

We are admirers of Rod Wong-managed RTW Bio. This trust is differentiated from most biotech or healthcare funds due to its dedicated focus on finding ‘transformative’ technologies.
Wong and his team have a track record of backing proven operators in the biotech patch. And the trust is now benefiting from a reopening of the IPO window and an improving wide market for biotech exits.
| AIC Healthcare & Biotechnology Sector | Discount/Premium to NAV | 1-yr share price total return |
| RTW Biotech Opportunities | -8.6% | +36.3% |
| International Biotechnology | -3.3% | +29.7% |
| Syncona | -28.2% | +26.6% |
| Biotech Growth | -8% | +25.4% |
| Polar Capital Global Healthcare | +0.7% | +18.7% |
Source: The AIC/Morningstar
In fact, Windward is the tenth ‘go-public event’ from RTW’s portfolio in 2026. This follows the IPOs of Aktis (NASDAQ:AKTS), Kailera (NASDAQ:KLRA), City Therapeutics (NASDAQ:CTY) and Lycia (NASDAQ:LYCA), as well as five reverse or SPAC mergers announced or completed.
Further realisations of private investments should help narrow the fund’s stubborn discount to NAV. To address this discount, the board has also committed a further $42.8 million to share buybacks.




